NDAINTRAVESICALPOWDER
Approved
Jun 2025
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
16
Data completeness
4/8 — Partial
ZUSDURI (mitomycin) by NeuroGenesis Bio is alkylating activity [moa]. First approved in 2025.
Drug data last refreshed 8h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZUSDURI is a mitomycin powder formulation administered intravesically (directly into the bladder) that works through alkylating activity to damage cancer cell DNA. It is used for intravesical chemotherapy in bladder cancer patients. The intravesical route delivers high local drug concentrations while minimizing systemic exposure.
Growth4.3 years to LOE
Early-stage growth product with minimal current commercial footprint; significant opportunity to build brand infrastructure and market presence from launch baseline.
Mechanism of Action
Alkylating Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
Started Sep 2022
201 enrolled
Colorectal CancerChemotherapy EffectSurgery+2 more
Safety and Efficacy of an Ab Interno Gelatin Stent (XEN63) With or Without Mitomycin C
Started Nov 2020
30 enrolled
Glaucoma, Open-Angle
Ab Interno Gelatin Stent With Mitomycin C Using Targeted Supra-tenon's Placement
Started Jun 2019
142 enrolled
Glaucoma
Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy
Started Mar 2019
19 enrolled
Glaucoma Open-Angle PrimaryGlaucomaOpen Angle Glaucoma+1 more
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
Started Jan 2019
50 enrolled
Urinary Bladder CancerInvasive Bladder Cancer
Worked on ZUSDURI at NeuroGenesis Bio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.